Best Milk thistle for Liver
Top 4 products ranked
Last reviewed May 2026
Clinical dose: 150–600 mg
Why Milk thistle for Liver
Milk thistle plays a key role in liver. Milk thistle contains silymarin, which is studied for liver-protective properties. Generally well tolerated. In clinical studies, milk thistle supports liver health and protection.
What dose to look for
Clinical studies typically use 150–600 mg of milk thistle. Silymarin extract range for liver support. Products below this range may not deliver meaningful results.
What form to look for
Avoid milk thistle powder — whole herb — very low silybin content, poor bioavailability. Avoid milk thistle seed — unextracted seed — very low bioavailability. Look for siliphos (silybin phytosome) or standardized silymarin (80%) for better absorption.
What the research says
Milk thistle has moderate clinical evidence for liver benefits. Multiple clinical trials on liver protection, but study quality and results are inconsistent Learn more
Clinical research on Milk Thistle (Silymarin)
HIGH — Cochrane review, multiple RCTs for hepatoprotection · 420–600 mg/day silymarin (standardized to 70–80% silybin)
- •Cochrane systematic review (2007, 18 RCTs, 1,088 patients) assessed milk thistle for alcoholic and hepatitis B/C liver disease. Found no significant effect on mortality or liver histology, but noted serious methodological limitations in available trials and called for higher-quality research. PubMed
- •SyNCH trial (2012, 154 patients with chronic hepatitis C non-responders) found intravenous silibinin significantly reduced HCV RNA, demonstrating potent antiviral activity — though this used IV administration, not oral. PubMed
- •2016 meta-analysis of 8 RCTs found silymarin significantly reduced ALT and AST levels in NAFLD patients, suggesting hepatoprotective benefit in fatty liver disease. PubMed
- •Widely used in integrative hepatology despite mixed trial data. Mechanism involves free radical scavenging, membrane stabilization, and anti-fibrotic activity via stellate cell inhibition. Oral bioavailability is poor (20–50%); phosphatidylcholine-complexed forms (Siliphos) improve absorption significantly.
- •Honest limitation: the Cochrane review conclusion was equivocal — milk thistle has not been shown to reduce mortality or improve hard clinical endpoints in liver disease. Most positive trials are for surrogate markers (liver enzymes), not patient-centered outcomes.
